A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine

Detalles Bibliográficos
Autores principales: Huang, Wei, Zeng, Zhan‐Cheng, Wang, Wen‐Tao, Sun, Yu‐Meng, Chen, Yue‐Qin, Luo, Xue‐Qun, Fang, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letter to Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967915/
https://www.ncbi.nlm.nih.gov/pubmed/33783997
http://dx.doi.org/10.1002/ctm2.355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967915/
https://www.ncbi.nlm.nih.gov/pubmed/33783997
http://dx.doi.org/10.1002/ctm2.355

Ejemplares similares